7 Recommendations For Building Your Brand With A Blog

Startup Professionals Musings

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. Here are some tips I’ve gleaned from experience: Lead with your blog.

FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns

Xconomy

Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study. The decision doesn’t halt the study entirely; it means that no new patients can be added.

Study 52

Will New Study Cut Guesswork for Depression Medicine Prescriptions?

Xconomy

Genetic testing that helps guide more precise cancer treatment is making its way into standard practice in major U.S. medical centers. Could the same eventually be true for depression?

Study 74

Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death

Xconomy

That’s according to a new study from University of California, Berkeley data scientists who analyzed the records of more than 400,000 people in the United Kingdom.

Study 88

Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data

Xconomy

Viking Therapeutics released preliminary results from a Phase 2 study suggesting its experimental drug might impact some of the disease’s many dangerous effects on the liver.

Study 86

Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study

Xconomy

A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.

Study 63

Study: Reflexion Health Virtual Therapy System Reduces Rehab Costs

Xconomy

The study, which evaluated Reflexion’s system for patients after total knee replacement surgery, was conducted in conjunction with the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.

Study 92

7 Keys To Utilizing A Blog To Drive Your Business

Startup Professionals Musings

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. Here are some tips I’ve gleaned from experience: Lead with your blog.

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Xconomy

In study results published Wednesday, the presence of the specific protein fragment that Epic (not to be confused with Verona, WI-based EHR software maker Epic Systems) tests for in circulating tumor cells predicted a shorter median length of survival for men whose disease has spread.

Study 103

Economic Study Ranks San Diego Near Top in Genomics Innovation

Xconomy

An economic impact study of San Diego’s emerging genomics industry counted 115 genomics-related companies operating in the region that directly employ over 10,000 people, and drive about $5.6 After previewing a glimpse of the study’s findings last month , Brady provided.

The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It?

Xconomy

Sixteen years ago, Kim Witczak’s husband died by his own hand, turning her world upside down. He had just begun taking an antidepressant off-label for insomnia, and she believes an undisclosed side effect of the drug drove him to suicide.

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

Xconomy

The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year. Last week, we featured two stories that you wouldn’t find at the ASCO frenzy: Immunotherapy’s lack of progress in treating breast cancer , and one woman’s risky bet of tens of millions of dollars from her personal fortune to speed drug development for the nastiest form of brain cancer.

Study 79

Kick-Start Your Consulting Startup With Your Blog

Startup Professionals Musings

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. Here are some tips I’ve gleaned from experience: Lead with your blog.

New Study: DNA Tests For Healthy People Have “Uncertain Value”

Xconomy

A new study published Monday in the Annals of Internal Medicine questions the practicality of making DNA tests standard for people who don’t have a cancer diagnosis or aren’t trying to identify a mysterious disease. The study is limited by its small scope, but it is the first with some rigor to examine outcomes. Genome sequencing is becoming more common for people diagnosed with cancer. Should it become part of a healthy person’s checkup, too?

Study 57

Study Stakes San Diego’s Claim in Genomics: $292M in 2016 VC Deals

Xconomy

Preliminary findings from an economic impact study show that genomics is emerging as a distinct innovation cluster in San Diego. The San Diego Regional Economic Development Corp.

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive

Xconomy

That included the Precision Medicine Initiative, an ambitious long-term study with the goal of recruiting 1 million Americans to volunteer health data. Until this week, many U.S. government science agencies and programs seemed destined for a big haircut, plus the loss of a limb or two.

Study 52

Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend Lives

Xconomy

Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they?

Guide 91

Every Consultant Needs a Blog More Than a Website

Startup Professionals Musings

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. Here are some tips I’ve gleaned from experience: Lead with your blog.

How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy

Xconomy

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America’s other biomedical hubs. Our goal is to make Columbus the center of the universe for gene therapy,” says Doug Ingram, CEO of Sarepta Therapeutics.

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

Xconomy

Merger merger and acquisition mice Modis Therapeutics Monica Forbes Multiple Myeloma Multiple Sclerosis neary opioid opioid cris Otezla passed away PCSK9 pharma PHASE # Praluent price Purdue Pharma Regeneron Pharmaceuticals Repatha Rhonda Chicko Richard Fitzgerald Richard Sackler RIP Rise Rodger Currie Rova-T Scholar Rock Scott Gottlieb SEngine PRecision Medicines Sesen Bio Stemcentryx Studies Symdeko Thomas Neff Tom Nearty Trial VC Venture Capital Vertex Zogenix

As U.S. Looks to Launch Precision Health Study, Google’s Role Emerges

Xconomy

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. To be clear, health data that citizens contribute to the study will be open for research under the purview of the government—not held privately by Google or the other two dozen entities that are building and running the four cornerstones of the PMI.

Study 63

Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer

Xconomy

There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.

Study 74

Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More

Xconomy

Merck Nasdaq NEA Nektar Therapeutics New Enterprise Associates Novartis Nuevolution NYSE opioid painkiller PatientsLikeMe pembrolizumab pricine Pricing regulation Rene Russo RNA Royalty Scott Gottlieb SCOTUS SMA Spinal Muscular Atrophy Study subsidiary T-cell therapy Tocagen US Supreme Court value Vas Narasimhan VC Venture Capital Voyager Therapeutics watchdog Zolgensma

Study 72

“Unseen Is Unsold:” VR & Analytics Study What and Why Shoppers Buy

Xconomy

Humans are great about saying a lot of things. We’re not that good about actually following through. See: New Year’s diet resolutions or election polls. That tendency affects retailers as well. Big stores and brands spend millions in market research to figure out what shoppers want and then model production and creative teams to create those items. What people say and what people do is different,” says Anne Stephenson, a partner with Explorer Research, which works with retailers and brands. “So,

Study 54

For a Services Business, a Blog Trumps a Website

Startup Professionals Musings

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. Here are some tips I’ve gleaned from experience: Lead with your blog.

For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs

Xconomy

Cassandra Trimnell has sickle cell disease. She also loves to travel. For her 30th birthday last year, she and her husband planned a trip to Indonesia, and she figured she would be fine.

Study 83

Recruitment Goal In Obama Precision Med Study: 1M in 3 or 4 Years

Xconomy

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

PMI 69

Cirius Therapeutics Raises $40M to Expand Ongoing Liver Study

Xconomy

A $40 million transfusion led by Frazier Healthcare Partners and Denmark’s Novo A/S is bringing fresh life to a Michigan biotech working to advance a new experimental drug for treating a type of non-alcoholic fatty liver disease.

Study 65

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

Xconomy

It’s the start of a plan whose seeds were planted more than two years ago, when former President Barack Obama proposed a study to glean insights about health and disease by tracking a large. An ambitious plan to recruit 1 million U.S.

Study 91

For More Lung Cancer Patients, the Promise of No Chemo Looms Larger

Xconomy

[ Editor’s note: Ben Fidler co-authored this report.] A decade from now, it’s possible that immunotherapy will have made a big dent in lung cancer, which is by far the deadliest type of the disease.

Study 77

Study: Users Not Willing To Pay To Use Twitter, Other Online Services

socalTECH

A study released Friday by the Center for the Digital Future, at the USC Annenberg School of Communications, finds that zero percent of Twitter users polled in the study would pay for Twitter. According to the study, it found that 49 percent of Internet users have used micro-blogging services like Twitter, but found that there was zero percent of users polled were willing to pay for such a service directly.

Study 147

Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More

Xconomy

Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try to find someone in the federal government who isn’t involved in the drug-price debate.

News 57

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Xconomy

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells from anonymous donors instead of from the same patients slated to receive the therapy, which is Juno’s method.

Doc 64

Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink

Xconomy

But the company is pinning its hopes on another Phase 3 study that will report data early next year. The study’s primary goal was to show, after 28 days, a resolution of symptoms without the need for additional antibiotics or treatment.

Study 52

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Xconomy

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P. Morgan Healthcare Conference and everything that mushrooms around it seem just as long as the holiday break—a distant memory!—that —that came just before. In 2020 (yes, that’s really a year), San Francisco might have a new mayor.